FDA Accepts Zingo Supplemental Drug For Pain Treatment

Armen Hareyan's picture
Advertisement

FDA has accepted Anesiva's electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is already approved by the FDA to provide local analgesia prior to peripheral IV insertions and blood draws in children three to 18 years of age.

Advertisement